{"celex_id": "32006D0540", "uri": "http://publications.europa.eu/resource/cellar/eea109d3-4fe6-4175-9caa-d387f1d63e1e", "type": "Decision", "concepts": ["1415", "212", "2739", "5782", "6400"], "title": "2006/540/EC: Commission Decision of  11 April 2006  on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2006 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council  (notified under document number C(2006) 1483)   (Text with EEA relevance)\n", "header": "4.8.2006 EN Official Journal of the European Union L 214/35\nCOMMISSION DECISION\nof 11 April 2006\non the allocation of quantities of controlled substances allowed for essential uses in the Community in 2006 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council\n(notified under document number C(2006) 1483)\n(Only the Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic)\n(Text with EEA relevance)\n(2006/540/EC)\nTHE COMMISSION OF THE EUROPEAN COMMUNITIES", "recitals": ",\nHaving regard to the Treaty establishing the European Community,\nHaving regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on Substances that Deplete the Ozone Layer\u00a0(1), and in particular Article 3(1) thereof,\nWhereas:\n(1) The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbon and bromochloromethane.\n(2) Each year the Commission is required to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them.\n(3) Decision IV/25 of the Parties to the Montreal Protocol on Substances that Deplete the Ozone Layer, hereinafter \u2018the Montreal Protocol\u2019, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party.\n(4) Decision XV/8 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the Sixth Meeting of the Parties, as well as Decisions VII/11, XI/15 and XV/5 of the Parties to the Montreal Protocol.Decision XVII/10 of the Parties to the Montreal Protocol authorises the production and consumption of the controlled substance listed in Annex E of the Montreal Protocol necessary to satisfy laboratory and analytical uses of methyl bromide.\n(5) Pursuant to paragraph 3 of Decision XII/2 of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free Metered-Dose Inhalers (MDIs), all Member States have notified\u00a0(2) the United Nations Environment Programme that chlorofluorocarbons (CFCs) are no longer essential for the manufacture of salbutamol CFC-MDIs for placing on the market of the European Community.\n(6) The Commission has published a Notice\u00a0(5) on 8 July 2005 to those companies in the Community of 25 Member States that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2006 and has received declarations on intended essential uses of controlled substances for 2006.\n(7) For the purpose of ensuring that interested companies and operators may continue to benefit in due time from the licensing system, it is appropriate that the present decision shall apply from 1 January 2006.\n(8) The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000,", "main_body": ["1.\u00a0\u00a0\u00a0The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2006 shall be 539\u00a0000,00 ODP\u00a0(6) kilograms.\n2.\u00a0\u00a0\u00a0The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2006 shall be 256\u00a0761,86 ODP kilograms.\n3.\u00a0\u00a0\u00a0The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2006 shall be 482,70 ODP kilograms.\n4.\u00a0\u00a0\u00a0The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 149\u00a0641,536 ODP kilograms.\n5.\u00a0\u00a0\u00a0The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2006 shall be 754,00 ODP kilograms.\n6.\u00a0\u00a0\u00a0The quantity of controlled substances of Group VI (methyl bromide) subject to Regulation (EC) No 2037/2000 that may be used for laboratory and analytical uses in the Community in 2006 shall be 300,00 ODP kilograms.\n7.\u00a0\u00a0\u00a0The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 4,49 ODP kilograms.\n8.\u00a0\u00a0\u00a0The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 13,308 ODP kilograms.", "The chlorofluorocarbon metered-dose inhalers listed in Annex I shall not be placed on markets where the Competent Authority has determined chlorofluorocarbonsfor metered-dose inhalers on those markets to be non-essential.", "During the period 1 January to 31 December 2006 the following rules shall apply:\n1. The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.\n2. The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.\n3. The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV.\n4. The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.\n5. The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.\n6. The allocation of laboratory and analytical critical use quotas for methyl bromide shall be to the companies indicated in Annex VII.\n7. The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VIII.\n8. The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex IX.\n9. The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex X.", "This Decision shall apply from 1 January 2006 and shall expire on 31 December 2006.", "This Decision is addressed to the following undertakings:\n3M Health Care Ltd\n3M House Morley Street\nLoughborough\nLeicestershire LE11 1EP\nUnited Kingdom\nBespak PLC\nNorth Lynn Industrial Estate\nKing's Lynn\nPE30 2JJ \u2014 Norfolk\nUnited Kingdom\non behalf of Boehringer Ingelheim (France)\nBoehringer Ingelheim GmbH\nBinger Stra\u00dfe 173\nD-55216 Ingelheim am Rhein\nChiesi Farmaceutici SpA\nVia Palermo, 26/A\nI-43100 Parma\nIVAX Ltd\nUnit 301 Industrial Park\nWaterford\nIreland\nLaboratorio Aldo Union SA\nBaronesa de Mald\u00e1, 73\nEspluges de Llobregat\nE-08950 Barcelona\nSICOR SpA\nVia Terrazzano, 77\nI-20017 Rho (MI)\nValeas SpA Pharmaceuticals\nVia Vallisneri, 10\nI-20133 Milano\nValvole Aerosol Research Italiana (VARI)\nSpa \u2014 LINDAL Group Italia\nVia del Pino, 10\nI-23854 Olginate (LC)\nAcros Organics bvba\nJanssen Pharmaceuticalaan 3o\nB-2440 Geel\nAirbus France\nroute de Bayonne 316\nF-31300 Toulouse\nBiosolove B.V.\nWaalreseweg 17\n5554 HA Valkenswaard\nNederland\nBie & Berntsen\nSandb\u00e6kvej 7\nDK-2610 Roedovre\nCarlo Erba Reactifs-SDS\nZ.I. de Valdonne, BP 4\nF-13124 Peypin\nCNRS \u2014 Groupe de Physique des Solides\nUniversit\u00e9 Paris, 7 Denis Diderot & Paris\n6 Pierre et Marie Curie\nF-75251 Paris Cedex 5\nHealth Protection Inspectorate-Laboratories\nPaldiski mnt 81\nEE-10617 Tallinn\nHoneywell Fluorine Products Europe\nKempenweg 90\nP.O. Box 264\n6000 AG Weert\nNederland\nHoneywell Specialty Chemicals\nWunstorfer Stra\u00dfe 40\nPostfach 100262\nD-30918 Seelze\nIneos Fluor Ltd\nPO Box 13, The Heath\nRuncorn Cheshire WA7 4QF\nUnited Kingdom\nInstitut Scientifique de Service Public (ISSeP)\nRue du Ch\u00e9ra, 200\nB-4000 Li\u00e8ge\nKatholieke Universiteit Leuven\nKrakenstraat 3\nB-3000 Leuven\nLGC Promochem GmbH\nMercatorstra\u00dfe 51\nD-46485 Wesel\nMallinckrodt Baker BV\nTeugseweg 20\n7418 AM Deventer\nNederland\nMerck KgaA\nFrankfurter Stra\u00dfe 250\nD-64271 Darmstadt\nMikro+Polo d.o.o.\nLackova 78\nSLO-2000 Maribor\nMinistry of Defense\nDirectorate Material RNL Navy\nPO Box 2070\n2500 ES The Hague\nNederland\nPanreac Qu\u00edmica SA\nRiera de Sant Cugat 1\nE-08110 Montcada I Reixac (Barcelona)\nSanolabor d.d.\nLeskov\u0161kova 4\nSLO-1000 Ljubljana\nSigma Aldrich Logistik GmbH\nRiedstra\u00dfe 2\nD-89555 Steinheim\nSigma Aldrich Chimie SARL\n80, rue de Luzais\nL'isle-d'abeau Chesnes\nF-38297 Saint-Quentin-Fallavier\nSigma Aldrich Company Ltd\nThe Old Brickyard\nNew Road Gillingham SP8 4XT\nUnited Kingdom\nSigma Aldrich Laborchemikalien\nWunstorfer Stra\u00dfe 40\nPostfach 100262\nD-30918 Seelze\nSigma Aldrich Chemie GmbH\nRiedstra\u00dfe 2\nD-89555 Steinheim\nTazzetti Fluids S.r.l.\nCorso Europa, 600/a\nI-10088 Volpiano (TO)\nUniversity of Technology Vienna\nInstitut of Industrial Electronics&Material Science\nGusshausstra\u00dfe 27-29\nA-1040 Wien\nVWR I.S.A.S.\n201, rue Carnot\nF-94126 Fontenay-sous-Bois\nYA-Kemia Oy \u2014 Sigma Aldrich Finland\nTeerisuonkuja 4\nFI-00700 Helsinki"], "attachments": "Done at Brussels, 11 April 2006.\nFor the Commission\nStavros DIMAS\nMember of the Commission\n(1)\u00a0\u00a0OJ L 244, 29.9.2000, p. 1. Regulation as last amended by Commission Regulation (EC) No 29/2006 (OJ L 6, 11.1.2006, p.\u00a027).\n(2)\u00a0\u00a0www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\n(3)\u00a0\u00a0Except Denmark.\n(4)\u00a0\u00a0Except Sweden.\n(5)\u00a0\u00a0OJ C 168, 8.7.2005, p. 20.\n(6)\u00a0\u00a0Ozone-depleting Potential.\nANNEX I\nPursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as \u2018essential\u2019 under the Protocol when combined with following active ingredients:\nTable 1\nCountry Short-acting Beta Agonist Bronchodilators\nSalbutamol Terbutaline Fenoterol Orciprenaline Reproterol Carbuterol Hexoprenaline Pirbuterol Clenbuterol Bitolterol Procaterol\nAustria X X X X X X X X X X X\nBelgium X X X X X X X X X X X\nCyprus X\nCzech Republic X X X X X X X X X X X\nDenmark X  X X X X X X X X X\nEstonia X X X X X X X X X X X\nFinland X\nFrance X\nGermany X X X X X X X X X X X\nGreece X X X X X X X X X X X\nHungary X X X X X X X X X X X\nIreland X\nItaly X\nLatvia X X X X X X X X X X X\nLithuania X X X X X X X X X X X\nLuxembourg X\nMalta X\nNetherlands X X X X X X X X X X X\nPoland X\nPortugal X X X X X X X X X X X\nNorway X X X X X X X X X X X\nSlovak Republic X X X X X X X X X X X\nSlovenia X X X X X X X X X X X\nSpain X\nSweden X\nUnited Kingdom X\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nTable 2\nCountry Inhaled steroids\nBeclomethasone Dexamethasone Flunisolide Fluticasone Budesonide Triamcinolone\nAustria\nBelgium X X X X X X\nCyprus\nCzech Republic X X X X X X\nDenmark X   X\nEstonia X X X X X X\nFinland X   X\nFrance X   X\nGermany X X X X X X\nGreece\nHungary X X X X X X\nIreland X   X\nItaly X   X X\nLatvia X X X X X X\nLithuania\nLuxembourg\nMalta    X X\nPoland\nPortugal    X X\nNetherlands X X X X X X\nNorway\nSlovak Republic X X X X X X\nSlovenia X X X X X X\nSpain X   X\nSweden X X X X  X\nUnited Kingdom    X\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nTable 3\nCountry Non-steroidal anti-inflammatories\nCromoglicic acid Nedrocromil\nAustria\nBelgium X X\nCyprus\nCzech Republic X X\nDenmark X X\nEstonia X X\nFinland X X\nFrance X X\nGermany X X\nGreece X X\nHungary\nIreland\nItaly\nLatvia X X\nLithuania\nLuxembourg\nMalta\nPoland\nPortugal X\nNetherlands X X\nNorway\nSlovak Republic X X\nSlovenia X X\nSpain  X\nSweden\nUnited Kingdom\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nTable 4\nCountry Anticholinergic Bronchodilators\nIpratropium bromide Oxitropium Bromide\nAustria\nBelgium X X\nCyprus X X\nCzech Republic X X\nDenmark X X\nEstonia X X\nFinland X X\nFrance\nGermany X X\nGreece X X\nHungary X X\nIreland X X\nItaly\nLatvia\nLithuania\nLuxembourg\nMalta X X\nNetherlands X X\nPoland\nPortugal X\nNorway\nSlovak Republic X X\nSlovenia\nSpain X X\nSweden X X\nUnited Kingdom X X\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nTable 5\nCountry Long-acting Beta Agonist Bronchodilators\nFormoterol Salmeterol\nAustria\nBelgium\nCyprus\nCzech Republic\nDenmark\nEstonia\nFinland\nFrance\nGermany X X\nGreece\nHungary\nIreland\nItaly X\nLatvia\nLithuania\nLuxembourg\nMalta\nNetherlands\nPoland\nPortugal\nNorway\nSlovak Republic\nSlovenia\nSpain\nSweden\nUnited Kingdom\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nTable 6\nCountry Combinations of active ingredients in a single MDI\nAustria\nBelgium\nCyprus\nCzech Republic\nDenmark\nEstonia\nFinland\nFrance\nGermany X\nGreece\nHungary\nIreland\nItaly\nLatvia\nLithuania\nLuxembourg\nMalta\nNetherlands\nPoland\nPortugal\nNorway\nSlovak Republic\nSlovenia\nSpain\nSweden\nUnited Kingdom\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nANNEX II\nESSENTIAL MEDICAL USES\nQuota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:\n3M Health Care (UK)\nBespak (UK)\nBoehringer Ingelheim (DE) on behalf of Boehringer Ingelheim France\nChiesi (IT)\nIVAX (IE)\nLab Aldo-Union (ES)\nSicor (IT)\nValeas (IT)\nV.A.R.I. (IT)\nANNEX III\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:\nAcros organics bvba (BE)\nBie & Berntsen (DK)\nBiosolve (NL)\nCarlo Erba Reactifs-SDS (FR)\nCNRS \u2014 Groupe de Physique des Solides (FR)\nHoneywell Fluorine Products Europe (NL)\nHoneywell Specialty Chemicals (DE)\nIneos Fluor (UK)\nKatholieke Universiteit Leuven (BE)\nLGC Promochem (DE)\nMallinckrodt Baker (NL)\nMerck KGaA (DE)\nMikro + Polo (SI)\nPanreac Qu\u00edmica (ES)\nSanolabor (SI)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nSigma Aldrich Logistik (DE)\nTazzetti Fluids (IT)\nUniversity of Technology Vienna (AT)\nANNEX IV\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:\nAirbus France (FR)\nIneos Fluor (UK)\nMinistry of Defense (NL)\nSigma Aldrich Chimie (FR)\nANNEX V\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:\nAcros Organics (BE)\nBie & Berntsen (DK)\nBiosolve (NL)\nCarlo Erba Reactifs-SDS (FR)\nHealth Protection Inspectorate-Laboratories (EE)\nInstitut Scientifique de Service Public (ISSeP) (BE)\nKatholieke Universiteit Leuven (BE)\nMallinckrodt Baker (NL)\nMerck KGaA (DE)\nMikro + Polo (SI)\nPanreac Qu\u00edmica (ES)\nSanolabor d.d. (SI)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nSigma Aldrich Laborchemikalien (DE)\nSigma Aldrich Logistik (DE)\nVWR I.S.A.S. (FR)\nYA-Kemia Oy (FI)\nANNEX VI\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:\nAcros Organics (BE)\nBie & Berntsen (DK)\nKatholieke Universiteit Leuven (BE)\nMallinckrodt Baker (NL)\nMerck KGaA (DE)\nMikro + Polo (SI)\nPanreac Qu\u00edmica (ES)\nSanolabor d.d. (SI)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nSigma Aldrich Logistik (DE)\nYA-Kemia Oy (FI)\nANNEX VII\nLABORATORY AND ANALYTICAL CRITICAL USES\nQuota of controlled substances of Group VI that may be used for laboratory and analytical critical uses are allocated to:\nSigma-Aldrich Chemie GmbH (DE)\nANNEX VIII\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:\nIneos Fluor (UK)\nKatholieke Universiteit Leuven (BE)\nSigma Aldrich Logistik (FR)\nSigma Aldrich Company (UK)\nANNEX IX\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:\nIneos Fluor (UK)\nKatholieke Universiteit Leuven (BE)\nSigma Aldrich Logistik (FR)\nYA-Kemia Oy (FI)\nANNEX X\n[This Annex is not published because it contains confidential commercial information.]"}